A New Era for Alzheimer's: The Push for Early Diagnosis Reshapes Lives

WASHINGTON, DC – May 13, 2026 – A major new awareness campaign launched today aims to fundamentally shift the public's understanding of Alzheimer's disease, moving the focus from the devastating late stages to the often-invisible early phases where life, agency, and purpose can still flourish. The campaign, called 'This is ALZ,' is powered by the nonprofit HealthyWomen and backed by a coalition of advocates who argue that a revolution in diagnostics and treatment demands a parallel revolution in perception.

For decades, the image of Alzheimer's has been one of profound memory loss and dependency. 'This is ALZ' seeks to replace that with the real faces of the more than 7 million Americans living with the disease, many of whom are in its earliest stages. The campaign spotlights individuals who are navigating diagnoses while maintaining careers, relationships, and personal goals, challenging the stigma that a diagnosis marks an end rather than a new beginning.

"People have that thought that your life ends when you get the diagnosis. But I felt like my life was just beginning," said LauraLee Denler, one of the individuals featured in the campaign who is living with early-stage Alzheimer's. Her story, along with others, forms the emotional core of a movement to empower patients through early awareness.

Redefining Life After Diagnosis

The campaign confronts a stark paradox in public health: while a near-unanimous 99% of Americans believe early diagnosis of Alzheimer's is important, fewer than one in five (16%) feel they know much about the disease. This knowledge gap is particularly critical for the communities most affected. Nearly two-thirds of Americans with Alzheimer's are women, and the disease disproportionately impacts older Black and Hispanic Americans, who are roughly twice and one-and-a-half times more likely, respectively, to have it than their white counterparts.

"Alzheimer's is commonly viewed as a disease that only impacts people in its most advanced stages, but the reality is far more nuanced," explained Beth Battaglino, RN-C, CEO of HealthyWomen. "By sharing real stories from people living with the earlier stages, This is ALZ aims to shift perceptions, encourage earlier conversations and help people better understand what's possible after diagnosis."

That possibility is a key theme. For many, the disease can be outwardly invisible in its initial phases. "My story is very different. People don't really get that I have Alzheimer's. They see me as kind of young," said Pako Rios, another campaign participant. This highlights the campaign's goal: to show that individuals can continue to lead meaningful lives, maintaining independence and a sense of purpose long after a diagnosis is confirmed.

Kerry Dennis, also living with early-stage Alzheimer's, emphasizes the power that comes with knowledge. "By being diagnosed early, I have a lot more opportunities," she stated. "It gave me the chance to make decisions about how I want to live my life."

The Dawn of Detection: A Revolution in Diagnostics

This push for a new narrative is not happening in a vacuum. It is being propelled by significant breakthroughs in medical science that are making early diagnosis more accessible than ever before. Until recently, a definitive Alzheimer's diagnosis often required invasive and costly procedures like spinal taps (lumbar punctures) or expensive PET scans, which are not always available.

Now, a new generation of diagnostic tools is changing the landscape. In the last two years, the U.S. Food and Drug Administration (FDA) has cleared several blood tests that can detect the key biological markers of Alzheimer's disease—amyloid plaques and tau tangles—with high accuracy. Tests like the Lumipulse, approved in May 2025 to measure pTau217 and beta-amyloid, and Roche's Elecsys pTau181 test, cleared in October 2025, offer a simpler, less invasive, and more affordable path to diagnosis.

These blood tests allow physicians, including those in primary care, to identify the disease's pathology in patients aged 55 and older who show signs of cognitive impairment. While not a standalone diagnostic, they provide crucial information that can accelerate the path to a confirmed diagnosis and subsequent care planning. This technological leap makes the 'This is ALZ' campaign's call for early awareness a practical and actionable goal for millions.

A Confluence of Interests: Awareness and New Treatments

Behind the 'This is ALZ' campaign is a powerful collaboration between the nonprofit HealthyWomen and the pharmaceutical giant Eli Lilly and Company. Lilly's support is strategically aligned with its own major advancements in Alzheimer's therapeutics. In July 2024, the company's drug donanemab (marketed as Kisunla) received FDA approval for treating early symptomatic Alzheimer's disease. It was the first amyloid plaque-targeting therapy to receive this specific designation.

Donanemab, and other drugs in its class, are designed to slow cognitive decline, not reverse it. Their efficacy is greatest when administered in the mild cognitive impairment or mild dementia stages of the disease. Therefore, a public health landscape where more people are diagnosed early creates a larger population of patients who can potentially benefit from such treatments. The success of these new-generation drugs is intrinsically linked to the success of early detection efforts.

This synergy between awareness and treatment underscores a new ecosystem in Alzheimer's care. Public health initiatives funded by pharmaceutical companies can raise ethical questions about influence, but they also represent a powerful alignment of interests that can accelerate change. As Karyne Jones, President and CEO of the National Caucus and Center on Black Aging (NCBA), noted, "Campaigns like This is ALZ are critical to broadening awareness, especially in communities like ours where greater understanding of the earlier stages of Alzheimer's is needed."

The Patient Perspective: Empowerment and New Challenges

Beyond the polished stories of a national campaign, the reality of an early diagnosis is complex. For many, it is an empowering moment that provides an explanation for confusing symptoms, ends a long and anxious "diagnostic odyssey," and unlocks a path forward. It allows individuals and families crucial time to plan for legal, financial, and future care decisions while the person with the diagnosis can still participate fully.

However, the experience is not without its profound difficulties. Patient advocacy groups report that receiving the diagnosis is often described as a "gut punch," bringing on waves of fear, anger, and anxiety. There is a difficult adjustment period as individuals learn to cope with changes in their cognitive abilities and confront the pervasive social stigma that still clings to the disease.

This stigma can lead to isolation, as people hesitate to share their diagnosis with friends, family, or employers. Furthermore, patients from minority communities often report facing significant barriers in the healthcare system, from a lack of culturally competent providers to experiences of being dismissed or misdiagnosed. The 'This is ALZ' campaign, by elevating diverse stories, aims to combat this stigma directly and encourage a more inclusive and responsive healthcare environment.

The campaign is rolling out across a new website, ThisisALZ.com, social media channels, and other educational platforms. By turning awareness into action, its organizers hope to convince the public, policymakers, and healthcare providers that the time to reconsider Alzheimer's is now. It marks a pivotal moment where patient voices, scientific innovation, and new therapeutics are converging, creating a new paradigm focused not on the end of a story, but on how the next chapters are written.